Anzeige
Mehr »
Montag, 22.06.2026 - Börsentäglich über 12.000 News
SEAS meldet US-Behörden-Compliance und plant neues Kobalt-Projekt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 867399 | ISIN: US9105711082 | Ticker-Symbol:
NASDAQ
18.06.26 | 15:30
7,070 US-Dollar
+0,43 % +0,030
Branche
Kosmetik
Aktienmarkt
Sonstige
1-Jahres-Chart
UNITED-GUARDIAN INC Chart 1 Jahr
5-Tage-Chart
UNITED-GUARDIAN INC 5-Tage-Chart
GlobeNewswire (Europe)
634 Leser
Artikel bewerten:
(2)

United-Guardian, Inc.: United-Guardian Reports First Quarter Results

HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share).

Donna Vigilante, President of United-Guardian, stated, "I am happy to report that sales and earnings increased in the first quarter of 2026 compared with the first quarter of 2025. Our financial performance was primarily driven by increased sales of both our pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose by 24% in the first quarter of 2026, driven primarily by increased demand for Renacidin, our most important pharmaceutical product. Sales of our cosmetic ingredients increased by 21%, with the increase primarily attributable to an increase in purchases by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients ("ASI"). ASI's purchases increased by 45% in the first quarter of 2026 compared with the first quarter of 2025. The lower purchases by ASI in 2025 were primarily the result of ASI carrying excess inventory, which suppressed its purchase levels. This excess inventory has now been worked off, and they have resumed regular purchase levels."

"In addition to the increase in sales, our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer ("CM") of Renacidin in connection with an unexpected shutdown at the CM's facility in late 2023, which resulted in lost Renacidin sales."

"With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our "natural" product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026."

United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.

Contact:Donna Vigilante
(631) 273-0900
dvigilante@u-g.com

NOTE: This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company's business please refer to the company's reports and filings with the Securities and Exchange Commission.

FINANCIAL RESULTS FOR THE
THREE MONTHS ENDED
MARCH 31, 2026 AND 2025

UNITED-GUARDIAN, INC.

STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended March 31,
2026 2025
Net sales - 2,872,222 - 2,481,127
Costs and expenses:
Cost of sales 1,447,789 1,123,076
Operating expenses 666,963 632,735
Research and development 115,021 114,394
Total costs and expenses 2,229,773 1,870,205
Income from operations 642,449 610,922
Other income:
Investment income 69,814 84,687
Net gain on marketable securities 17,742 12,350
Settlement income 303,133 ---
Total other income 390,689 97,037
Income before provision for income taxes 1,033,138 707,959
Provision for income taxes 214,236 147,064
Net income - 818,902 - 560,895
Earnings per common share (basic and diluted) - 0.18 - 0.12
Weighted average shares (basic and diluted) 4,594,319 4,594,319

© 2026 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.